Cystic fibrosis (CF) is an autosomal recessive, life-limiting, genetically inherited disease. It is a multi-system disorder and results from one of several identified...
Added 9 days ago Drug news
Phase III ARRIVAL data on Kalydeco in cystic fibrosis published in The Lancet Respiratory Medicine.- Vertex Pharma.
Vertex Pharmaceuticals announced data from the ongoing Phase III, open-label ARRIVAL study and published online in The Lancet Respiratory Medicine...
Added 1 month ago Drug news
VX 445 + tezacaftor + ivacaftor combination for cystic fibrosis patients with a F508del mutation enters Phase III studies.- Vertex
Vertex Pharmaceuticals Incorporated announced that it is initiating two Phase III studies of VX 445, tezacaftor and ivacaftor as an...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life.
Added 5 days ago
Specialised CF care has led to a dramatic improvement in survival in CF: in the last four decades, well above what was seen in the general population over the same period.
Added 4 years ago
Palliative care is an approach that improves quality of life for patients and their families facing problems associated with a life-threatening illness. Care planning is particularly important in CF...
Added 7 years ago
Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
Background: To determine in vivo effects of CFTR modulators on mutation S945L.
Added 4 months ago
Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
The CFTR potentiator, ivacaftor (IVA), has been widely used in the treatment of cystic fibrosis (CF) patients with the G551D mutation. To date, there has been limited information on the microbiological status...
Added 4 months ago
- Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- Registration required
- Subscription fee